{"url_path":"/sec/coag/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/2114044/0001193125-26-234386-index.html","accession_number":"0001193125-26-234386","cik":"0002114044","ticker":"COAG","issuer_name":"Hemab Therapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2114044/0001193125-26-234386-index.html","primary_entity_key":"0002114044","primary_entity_name":"Hemab Therapeutics Holdings, Inc."},"word_count":63,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nDirector and Officer Trading Arrangements\n\nNone of our directors or officers (as defined in Rule\n16a-1(f)\nunder the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule\n10b5-1\ntrading arrangement or a\nnon-Rule\n\n10b5-1\ntrading arrangement (as defined in Item 408(c) of Regulation\nS-K)\nduring the quarterly period covered by this report.\n\n \n\n107\n\n##### Table of Contents"}